Progyny (PGNY) has drawn investor attention after recent trading, with the share price last closing at US$22.77 and mixed returns over the past year, including a decline over the past month and a gain over the past 3 months.

The recent 30 day share price return of a 14.59% decline, alongside a 7.17% drop over the past week, contrasts with a 26.43% gain over 90 days. Meanwhile, the 1 year total shareholder return of 0.22% and 5 year total shareholder return of a 53.36% decline point to fading longer term momentum.

If Progyny has put fertility benefits on your radar, it could be a good moment to scan other healthcare names using our healthcare stocks.

With Progyny trading at US$22.77 against a price target near US$30.91 and an indicated intrinsic discount of around 69%, you have to ask yourself whether this represents a genuine opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 22.6% Undervalued

Progyny’s widely followed narrative sets a fair value of $29.40 per share, which sits comfortably above the recent $22.77 close and anchors a more optimistic view.

Analysts have modestly raised their fair value estimate for Progyny from $28.25 to $29.40 per share, citing emerging positive catalysts, stronger expected utilization on higher eligible lives, and potential incremental tailwinds from expanding IVF awareness and coverage.

Curious what underpins that higher fair value, beyond headlines about IVF coverage and awareness. Revenue assumptions, margin shifts, and future earnings all play a central role. Want to see how those moving parts fit together in one coherent growth path.

Result: Fair Value of $29.40 (UNDERVALUED)

However, the story can change quickly if employers tighten benefit budgets or if political and regulatory shifts around reproductive health limit demand for IVF and related services.

Another View: Earnings Multiple Sends a Caution Flag

Here is the tension. While the most popular narrative points to Progyny trading below fair value, the current P/E of 34.7x sits well above both the US Healthcare industry average of 22.5x and the estimated fair ratio of 22.4x. This suggests the market could move toward a lower earnings multiple. Is this a margin of safety, or a signal that expectations are already running hot?

Build Your Own Progyny Narrative

If you read this and think the assumptions miss something, or you prefer to work directly with the numbers, you can build your own view in minutes by starting with Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Progyny.

Ready for more investment ideas?

Do not stop at a single company view. Widen your opportunity set by scanning pre filtered ideas that match different goals, income needs, and risk levels.

• Target potential mispricing by checking out these 863 undervalued stocks based on cash flows which is built around discounted cash flow assessments and cash flow strength.
• Position yourself early in structural tech themes by reviewing these 28 AI penny stocks which is tied to artificial intelligence growth stories.
• Boost your watchlist with income focused names by screening these 11 dividend stocks with yields > 3% which already clears a 3% yield hurdle.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.